Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides free water and calories to correct carbohydrate depletion and osmotic diuresis. Potassium chloride replaces potassium ions to maintain cellular membrane potential, nerve impulse conduction, and muscle contraction. Sodium chloride 0.11% provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Fluid and electrolyte replenishment,Intravenous maintenance therapy for patients with low potassium and sodium requirements,Correction of hypokalemia (when chloride loss is present)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; rate and volume determined by electrolyte needs and fluid status. Typical maintenance: 1-2 m Eq/kg/day potassium chloride, administered at a rate not exceeding 10-20 m Eq/h via peripheral line or up to 40 m Eq/h via central line. This product provides 0.037% KCl (5 m Eq/L), 5% dextrose, and 0.11% Na Cl (19 m Eq/L Na+).
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Potassium: not applicable as an element; distribution half-life ~1 h. Dextrose: minutes. Sodium: regulated with t1/2 of ~1-2 h for acute load.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the Krebs cycle; potassium and sodium are not metabolized but are excreted renally.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: >90% of potassium is excreted via kidneys, with minor fecal loss (~10%). Dextrose and sodium are fully metabolized or renally excreted.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Potassium: negligible (<2%). Dextrose: none. Sodium: none.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Potassium: ~0.5 L/kg (total body water). Dextrose: ~0.2 L/kg (extracellular fluid initially). Sodium: ~0.2 L/kg (extracellular space).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
IV: 100% for all components. Oral: not relevant for IV formulation.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²) unless hypokalemia is documented and close monitoring is possible. For e GFR 30-60 m L/min/1.73 m²: reduce infusion rate and total daily dose by 50% with frequent serum potassium monitoring. Use with caution in acute renal failure.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustment required for Child-Pugh class A or B. For Child-Pugh class C: monitor serum potassium closely due to risk of hyperkalemia, especially with concomitant diuretics or renal impairment; consider lower infusion rates and total doses.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Dose based on weight: usual maintenance potassium chloride 2-4 m Eq/kg/day IV infusion. For infants and children <25 kg: maximum infusion rate 0.5-1 m Eq/kg/h, not to exceed 20 m Eq/h. This product provides fixed concentrations; adjust infusion rate accordingly to avoid exceeding potassium infusion limits.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to age-related decline in renal function. Start at lower end of dosing range (e.g., 20-40 m Eq/day) and titrate slowly. Monitor serum potassium, renal function, and volume status frequently. Avoid rapid infusion rates.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May cause hyperkalemia if potassium excretion is impaired or if given too rapidly,Risk of volume overload in patients with cardiac or renal impairment,Administration may cause dilutional hyponatremia and hyperglycemia,Monitor serum potassium, sodium, glucose, and fluid balance regularly,Avoid use in patients with hyperkalemia, hypernatremia, or hyperglycemia,Use caution in patients with impaired renal function or Addison's disease
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia,Hypernatremia,Hyperglycemia,Severe renal impairment with oliguria or anuria,Acute intracranial hemorrhage (due to free water load),Patients with known allergy to any component
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid excessive dietary potassium (bananas, oranges, potatoes) if serum potassium is high. This product is often used in hospital settings; patients should follow dietary restrictions as directed by their physician.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No teratogenic effects are expected when used at recommended doses. However, maternal electrolyte imbalances (e.g., hyperkalemia, hyperglycemia, hypernatremia) may indirectly affect fetal development. First trimester: No known increased risk; second/third trimester: risk of fetal acidosis or hyperglycemia if maternal levels are severely altered.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Potassium, glucose, and sodium are normal constituents of breast milk. Exogenous administration at therapeutic doses is unlikely to affect milk composition significantly. No specific M/P ratio available; minimal risk expected. However, monitor infant for signs of electrolyte imbalance or glucose dysregulation if maternal doses are high.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy may increase plasma volume and glomerular filtration rate, potentially altering electrolyte and glucose distribution. No specific dose adjustment required for potassium, dextrose, or sodium chloride at standard replacement doses, but monitor for increased requirements or hyperglycemia due to gestational insulin resistance. Adjust rate of infusion based on ongoing losses and serum levels.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
This combination provides maintenance fluid and electrolytes. Use with caution in patients with renal impairment or conditions predisposing to hyperkalemia. Monitor serum potassium and glucose levels, especially in diabetic patients. Do not administer simultaneously with blood products. Check for compatibility with other additives.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This solution is used to provide fluids and electrolytes to your body.,Tell your doctor if you have kidney problems, diabetes, or are on a potassium-restricted diet.,Inform your healthcare provider about all medications you are taking, especially potassium supplements or diuretics.,Report any signs of allergic reaction, swelling, or shortness of breath during infusion.,Do not stop the infusion without medical advice.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose 5% provides free water and calories to correct carbohydrate depletion and osmotic diuresis. Potassium chloride replaces potassium ions to maintain cellular membrane potential, nerve impulse conduction, and muscle contraction. Sodium chloride 0.11% provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by electrolyte needs and fluid status. Typical maintenance: 1-2 m Eq/kg/day potassium chloride, administered at a rate not exceeding 10-20 m Eq/h via peripheral line or up to 40 m Eq/h via central line. This product provides 0.037% KCl (5 m Eq/L), 5% dextrose, and 0.11% Na Cl (19 m Eq/L Na+).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No teratogenic effects are expected when used at recommended doses. However, materna. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.